Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22527350,maximum plasma concentrations,Methantheline reached maximum plasma concentrations of approximately 25 ng/ml after 2.5-3 h and was eliminated at an apparent half-life of approximately 2 h.,Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),[ng] / [ml],25,210062,DB00940,Methantheline
,22527350,apparent half-life,Methantheline reached maximum plasma concentrations of approximately 25 ng/ml after 2.5-3 h and was eliminated at an apparent half-life of approximately 2 h.,Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),h,2,210063,DB00940,Methantheline
,22527350,"concentration at half maximum effects, EC₅₀)","Methantheline reduced salivation at a potency (methantheline concentration at half maximum effects, EC₅₀) of 5.5 ng/ml in accordance with it plasma concentration.",Relative bioavailability and pharmacodynamic effects of methantheline compared with atropine in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527350/),[ng] / [ml],5.5,210064,DB00940,Methantheline
